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Abst ract
The treatment ofschizophrenia was reuolutionizedwith the introduction cfchlorpromaeine in
1952. The dfectiveness qfchlorpromazine in controlling psychotic symptoms lead to the dopamine
hypothesis ofschizophrenia, which revolutionized our conceptualization ofthis illness. Si nce that
time, numerous typical antipsychotic drugs have been developedfo r the treatment ofschizophrenia.
However, the introductionofclozapine in 1990 began a new era in thepharmacologic management
qfschizophrenia. Clozapine, an atypical antipsychotic drug, is dfective in controlling the positive
symptoms ofschizophrenia in a large numberofotherwise treatment-resistant patients, and also
improves the negative symptoms qf the illness in marry patients. Clozapine is classified as an
atypical antipsychotic drug because it has little potential for causing extrapy ramidal side dfects,
and its effects on dopaminergic and serotonergic neurotransmittersystems are unique compared with
thoseoftypical antipsychotic medications. The effectiueness ofclozapine and theexplosion ofresearch
in neuroscience has led to the investigation qf neurotransmitter systems other than dopam ine as
important in developing pharmacologicstrategiesfo r the treatment ofschizophrenia. This paper will
review current pharmacologic advances in the treatment ofschizophrenia, and highlight the clinical
findings and use qfclozapine, theprototype qfa new generation qfantipsychotic drugs.
INTRODUCTION
Schizophre nia was classified as a synd ro me almost 100 years ago, a nd whi le th is
illn ess was well cha rac te r ized by Kraepelin , Bleu ler a nd othe rs, adeq uat e t rea tmen t
for this disorder did not become avai lable until th e 1950 's. Earl ier t rea tments
included hydrotherapy, insulin shock th erapy, elec t roconvulsive t herapy, and fronta l
lob otomy. However in 1952 , with th e int roducti on of chlorpromazine , the treatment
approach to schizophre nia was ra dica lly cha nged. Fo r th e firs t ti me, a med ica tion was
available that was effec t ive in con t rolling psych oti c sym pto ms in a large num ber of
patien ts . Patients improved enough to benefit from other th erapi es, including
support ive and gro up psychotherapy, recr eational th erapy a nd occupa tional th erapy.
These mod alities could now be used effec t ively to provide lon g-term psychosocial
rehabilitation in orde r to improve th e quality of life of patients with schizophreni a .
The well kn own pharmacologic effec t of dopamine (DA) blockad e by chlorproma-
zin e lead to the dopamine hypothesis of sch izophrenia whi ch truly revolutioni zed our
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conce p tualiza t ion of this illn ess, a nd served as a maj or impetus to intensely scru tinize
th e neuroch emistry of th e disorder ( 1,2). Subse q ue nt to the introduction of chlor-
promazine, numerous othe r dopamine blocking agents, ini tially ca lled "neu rol eptics"
becau se they have th e inherent ris k of pr oducin g ex t rapyra midal neurological side
effec ts, have become available for th e treatment of schizop hr enia. The introduct ion
of clozapine beg an a new era in th e ph armacologic management of schi zophrenia .
C loza pine beca me th e first true "atypica l" an tipsycho tic med ication avai lable for
clinica l use. Antipsychotics classified as "atypica l" genera lly include th e following
characte r istics : th ey (I) do not ca use ca tale psy in animal models, (2) ca use minimal
or no ex trapyra m idal sym ptoms (EPS) in hu m ans, (3) have little effec t on plasm a
pr olactin conce ntra t ions (typical a n tipsychot ics increase plasma prolactin) , (4) have
greater 5-HT 2 receptor blockad e th an typica l a n t ipsychot ic medi cations, (5) tend to
have more D, receptor blockad e th an typical a n t ipsychot ics. T hus, atypical an t ipsy-
chotics such as clozapine have minimal or no liab ilit y for producing movement
di sorders, a tremendous advan tage cons idering a pproximately 15-20 percent of all
patients on lon g-t erm a ntipsycho t ic drugs develop tardive dys kin esia, and a nother I
percent develop ta rdi ve dystonia (3-5).
The recent explosion of research in neuroscience and th e effec t iveness of th e
a typica l a n tipsychot ics has led to the investigat ion of neurot ransmitt er syst ems other
than dopamine as important ph a rm acological strategies for th e treatment of schizo-
phrenia. Other syste ms under invest igat ion that have been implicated in th e patho-
ph ysiol ogy of sch izophre nia include seroto nin (5-HT) , o -opioid , neurot en sin (NT),
a nd N-methyl-D- asparta te (NMDA) .
This pap er will review th e ph armacological strategies used in th e developmen t
of new an ti psycho tic drugs, as th e patho physiology of schizophrenia becomes further
elucidate d . Numerous medi ca tion s, incl uding many atypica l antipsychotic drugs, are
a t va rious stages in clinical t ri als, and some will become avai lable for clini cal use in
th e near future. Since clozapine is curren tly th e only atypical antipsychotic drug
ava ila ble for use, it will be add res sed in det ail.
Pharmacological S trategies
The dopaminergic syste m has t ra d itionally been th e primary focus of man y
inves t igational drugs du e to th e efficacy of D2 antagonists in controlling th e positive
sym ptoms (eg. hallucin ations, delu sion s) of schizophrenia (1,2) . Drugs that are
se lec tive D2 an tagonist s have proven to be clinically useful , yet the potential for th e
development of EPS and tardive dysk inesia remains rela tively high, which is a major
di sadvantage . Drugs in this class include th e benzamides su lp irid e (the protot ype),
racloprid e a nd re mo xipride; stud ies have demonstra ted that the la tt e r two medi ca-
tion s a re efficacious and well -tolerated , a nd th ey may receive FDA approval soo n (6).
T ergu rid e is a partial D2 agoni st that may be effective in alleviating both positive
a nd negative sym pto ms (eg. blunted affect , socia l isola tion) of schizophrenia (7) .
Part ial D2 agonists are capable of up or down regulating different dopaminergic
pathways by increasing or d ecreas in g ne uro t ra ns miss ion in hyp o- or hyper-
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functioning pathways, resp ectively. The hypoth esis th at th ere is a reducti on of
syna pt ic DA in th e front al cor te x whi ch results in th e nega t ive symptoms and an
incr ease in syna pt ic DA in th e mesolimbic syst em resulting in posit ive symptoms has
led to th e use of partial ag onists to modulat e th ese circu its.
The identification of multiple subtypes of DA receptors has led to th e develop-
ment of other hypotheses in addition to Dzdysr egul ation. Pr eferent ial D , antagonism
(D ) > Dz) seems to play a n important rol e in th e treatment of many schizophrenic
patients (7,8). Severa l drugs have recently been identified that are mu ch mor e
se lec tive for D ) receptors, without strong cho line rg ic, seroto ne rgic, and noradren cr-
gic activity (7). Pr eferential D ) antagonist s appea r to have very littl e pot ential for
producing EPS , whi ch may imply th at th e ratio of D,:Dz blockad e is an important
fac to r in th e development of EPS.
There a re several se ro to nin-based s t ra tegies, a nd 5-HT z antagonists seem to be
particul a rly pr omisin g (6, 7,9) . It has been postulated th a t blockade of 5-HT z recep -
tors is th e mechanism responsibl e for th e success of cloza pin e in improving th e
neg ative sym ptoms of schizophrenia. Other drugs wit h significan t 5-HT z blocka de
include Auperlapine, sertindole, ola nzapine , a nd risp eridon e, which has recent ly been
filed with th e FDA a nd is awa it ing a pproval. Addit ionally, 5-HT3 an tagonists a nd
5-HT) a agonists a re a lso under inves tiga t ion; however, th e ant ipsychotic efficacy of
th ese ag ents is not well es tablishe d.
The rol e of o-opioid receptors in the pathophysiolo gy of schizophrenia is also
under investigation (7, 10) . This approach is based on evide nce th a t typ ica l a n tipsy-
cho t ic drugs, suc h as haloperidol, have an affinity to th e rr-opioid receptor, a nd it has
been postulat ed th at this may cont ribu te to th e a nt ipsychotic efficacy of th ese
medi cation s. It has also been demonstrat ed th at remoxipride has an affinity to th e
rr-opioid receptor. The o-opioid a n tagonist rimcazole has been di sappoint ing how-
eve r, du e to bo th it s lack of efficacy a nd an unfavorabl e side effec t profile, including a
relatively high incid en ce of se izures (7) .
Neurote ns in (1\'1'), a n endoge no us tridecapeptide, possesses many ph armacologi-
ca l pr op erties in com mo n with a typica l a nt ipsychotics (II ). It has been demonst ra ted
th at both typical a nd at ypical a nt ipsychot ic dru gs incr ease NT concen t rat ions in th e
nucleu s acc um be ns, a nd typical a n t ipsycho tics increase NT conce n trations in th e
ca uda te nucleu s as well ( 12- 14). The develop ment of l\TT agonists will a llow its role in
th e pathophysiology of schizo phrenia to be further elucida ted .
NMDA agonism may provide ye t a no the r promisin g ap proach to th e dev elop-
ment of a typica l antipsych oti c drugs. The ph en cyclidine (PC P) /NMDA model of
schizophre nia hypothesiz es th at th ere is a relative decr ease in glu tama te rg ic neuro-
transmission du e to inhibition of th e NMDA type of glu tamate receptor (15,16). This
mod el was origina lly pr op osed a fte r numerou s pat ien ts wit h PCP intoxication
present ed with a clini cal picture indistingui sh abl e fro m schizophre nia , including th e
pr esen ce of both positive and negative sym ptoms (16) . Therefore, NMDA agon ists
ca pa ble of incr easin g glu tamate rg ic/NMDA neurot ran smission may prove to be very
useful. Medi ca tions developed thus far ha ve been int olerabl e for pa t ien ts, and
curre n t ly th ere a re no drugs in clinical use. However, t he addit ion of the amino ac id
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glycine , a co-agonist a t the NMDA receptor com plex, to typical antipsychot ic
medi ca tions has proven to be a useful adj uva n t for some pa t ien ts ( 17,18).
Clozapine
C lozapine was developed over thirty yea rs ago, and has be en used ext en sively in
Europe since th e 1960 's. Shortly a fte r th e st udy publish ed by Shopsin e t al ( 1979) ,
clozapine was banned from furth er inves tiga tio n in th e United St ates du e to a
number of fa tal cas es of ag ranulocytosis associa ted wit h it s use ( 19) . However,
cloza pin e was reintroduced into the Uni ted States severa l yea rs lat er, and th e
hall ma rk study by Ka ne et a l ( 1988), demon stra ting its efficacy in treatment-
res istant schizophre nic patients, led to it s even tua l a pproval by th e FDA in 1990. The
approval had th e st ipu la t ion th at weekly white blood counts (WBC s) woul d be
monitored in patients in order to det ect th e rare occura nce of agranulocytosis (20) .
Clozapine is cur re n t ly indica te d for use in patien ts who a re t reatment-resist ant ,
loosely defin ed as those who have fail ed trials of severa l di fferen t typical an tipsych oti c
drugs, or in patients who are un abl e to tolerate typical ant ipsychotic drugs du e to
severe side effects, including tardive dyskinesia.
Pharmacology
C lozapine is a dib enzod iazepi ne th at is chemica lly relat ed to th e typical a nt ipsy-
cho t ic loxapine (2 1). C loza pin e is not a selective DA an tagonist ; in fact it has grea ter
affinity for cho line rg ic (m uscarinic), serotonergic, norad renergic (a ) and ( 2), a nd
histaminergic (H) ) receptors th an for dopaminergic recept or s (22-25). Whi le th e
precise mech anism of ac tion is unknown, man y a u thors have pos tula ted tha t th e
5-HT 2 a n tagonism of clozapine acco un ts (a t least in part ) for its efficacy, espec ially
with regard to im proveme nts in nega tive symptoms commonly obs erved in pa tients
(6). Blockad e of th e nor adrenergic, hist amine rgic an d cho linergic receptor s, whil e
no t th ou ght to be respo ns ible for any therapeutic act ions of clozapine, are responsible
for many of the d rugs side effec ts .
C loza pine, un like typical a n t ipsycho t ics, binds pr eferentially to OA receptor s in
th e mesocor t ica l and mesolimbic regions of th e brain (i6) . In addit ion, clozapine has
a relatively grea ter affinity for th e 0 1 rece ptor com pa re d wit h the O2 receptor (26) .
These properti es may expla in why clozapine has a very low incidence of EPS. Farde et
a l (1992) demon strat ed with positron emiss ion tomography th at O2 receptor occu-
pancy in th e basal gang lia of patients t reat ed with clozap ine was 38% to 63%,
sig nificant ly lower tha n th e 70% to 89% th a t was found in pa tients on typical
a nt ipsycho t ics, indicating less nigrostriatal blockad e in pa tient s on clozapine (27) .
Further evidence support ing th e rela t ive se lect ivity of clozapine for dis cret e dop a mi n-
ergic pat hways is th at its effects on th e tubero infundi bul a r syste m is minimal a nd
transie nt. This is based on evidence that plasma prolactin conce nt ra t ions are not
eleva te d in pa t ien ts on clozapine therapy, except for an initia l marginal incr ease th at
is occasionally observed whi ch ra pid ly re turns to baseline with con t inue d treatm en t
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(28,29) . This is in con trast to typical an t ipsychot ics, whi ch elevat e plasma prolactin
conce n t ra t ions throughout th erapy (30).
Pharmacokinetics
The bioavailability of clozapinc varies markedl y a mo ng published repor ts, bu t
averages 50 to 60 percent of the oral do se, and mo st of th e d ru g is pro tein bound (21) .
Peak plasma conce n t ra tions are a ttaine d ab out 2 hours afte r inges tion, and side
effec ts, especia Ily orthostatic hypotension, typicall y peak a t this t ime (21). T he
met abolism of clozapine is com plex, as it unde rgoes multiple ox idation reactions a nd
demethylation in th e liver, resulting in 80% of th e drug being excreted as metabolites
(31 ,32). The half-life elimina tion of cloza pine is 12 to 16 ho urs, whi ch allows for
convenien t twic e-a-d ay dosing. Plasma drug levels in the range of 200 to 400 ng /ml
are commo n in patients on a typical do se of 300 to 500 mg/day (2 1). In it ially, plasma
drug conce n t ra t ions did not seem to corre la te we Il with drug response; however,
more recent data indicates that th e maj orit y of patien ts who res po nd to clozapine
have drug levels of 350 ng /ml or greate r (Me ltze r, unpublish ed dat a ). Furthermore,
nonresponders with blood levels below 350 ng /ml have conve r te d to responders by
incr easing th e dos e of cloza pine to achi eve this minimum plasm a con centrat ion .
Therefore, in at least a subpopulation of patients, plasm a drug concentrations
corre la te weIl with clini cal response to c1ozapine.
Clinical Response
There have been numerous cont ro lled trials comparing th e efficacy of typical
antipsychotics with c1ozapine. Shopsin et al (197 9) cond uc te d a double-blind compari-
son of clozapine a nd chlorpro maz ine in th e t reatment of ac u te ly psych ot ic sch izo-
phrenic patients and found clozapine was eq ual or superior to chlorpromazine in
cont roIling psychotic sym ptoms (19) .
H owever, it was th e hallmark, multicenter study by Kane et a l (1988) that clearly
establishe d the efficacy of cloza pine in treatment-resist an t sch izophr enic patients
(20). This study included patients who met DSM-III cr iteria for schizo ph renia a nd
who had pr eviously fail ed to respond to a t least 3 different typical ant ipsychotic
drugs . Patients initially underwent a prosp ective, sing le-blind tria l of haloperidol
(m ean dosage 6 1 mg/day) for six week s. Eighty percent (268) of th e pat ien ts fai led to
respond, a nd were randomized in a double-blind manner to treatment wit h eithe r
cloza pine (up to 900 mg/day) or chlorpro mazine (up to 1800 mg/day). After six
weeks, 30% of patients in th e c1ozapine-treat ed gro up were classi fied as respond ers
com pa re d with 4% in th e chlor pro mazine -t reate d gro up. It was a lso noted th at
negative, as well as positive, symptoms improved in patients who received c1ozapine.
In a recent study by Pickar e t al (1992) , 21 patients with schizophrenia who were
eit he r treatment-resistant or unable to tol erate typical a n t ipsycho tic medicat ions
were enro lled in a crossover , pla cebo- controlled , double-blind com pa rison tria l of
clozapine a nd fluphen azine (33). Thirty-eight percent (n = 8) of th e pa tien ts demon-
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strated greater improvement with c1ozapine, and clozapine significa nt ly red uced
bot h pos it ive a nd negat ive symptoms com pa red with fluphenazin e and placebo. No
improvement in negative symptoms was obs erved with fluphenazin e trea tmen t or
pla cebo. It was al so found that low ratios of ce re brospina l fluid homova nill ic acid (a
me tabolite of DA) to 5-hydroxyindoleacet ic ac id (a metabolite of se ro to nin) pr e-
d icted cloza pine superiority, suggesting that a n imbalan ce. between t hese two sys-
tems may be responsible for producin g some symptoms of schizo phrenia, and that th e
dual act ion of clozapine on both DA and 5-HT syst em s correc ts thi s imbal an ce. In
addit ion, pa t ients who experienced significant EPS with fluphenazin e treat ment had
a more favorable respon se to c1ozapine.
Clinical Use
C lozapine is current ly available as sco red 25 mg a nd un scored 100 mg table ts.
Pa t ien ts are typica lly s ta r ted on 25 mg twice-daily, but elde rly patients may need to
begin with 12.5 mg daily. The dos e is titrated upward by 25 to 50 mg every day (or in
12.5 mg incr ements in th e elde rly) as tolerat ed. Rapid up wa rd ti tra tion ma y be
limited by adverse effec ts, mo st notabl y orthostatic hypot ension a nd seda tion. If
pat ients are in itiat ed on clozapine th erapy on an outpatient basis, less aggressive
titration is recommended sin ce patients ca nno t be closely mon itored . Although th ere
is a wid e range of reported effec t ive daily dos es (fro m 25 to 900 mg), a dose of 300 to
500 mg per day has been shown to be th e effec t ive do se range for th e maj ori ty of
schizophrenic patients (21).
What const it u te s an ad equate trial of cloza pine is st ill being det ermined , bu t it is
clear that many pat ients may not show any significant improvement unt il 3 to 6
months in to th erapy (Meltzer , unpublish ed data) . Furthermore, many pa tien ts
demonstrate con t inua l improvement afte r 6 to 12 months of cloza pine t reat men t (6).
This seems to-be a unique feature of c1ozapine, and e m phas izes th e importan ce of a
long-ter m tria l before the drug is discontinued in a patient du e to pr esumed Jack of
efficacy .
Clozapine treatm ent should not be initiated in patients with a his tory of a
myeloproliferat ive disord er, previous c1ozapine-induced gra nulocytope nia or agranu-
locyt osis, or a WB C of less than 3500 /mm3. A rela tive con t raindica tion to trea tmen t
with cloza pine includes con current use of other medi cations with th e pot en tial for
bone marrow suppression (ie. carbamazepine) . Additionally, th e coad minist ra t ion of
clozapinc wit h benzodiazepines should be do ne with ca u tion because of several
reports of sudden death in patients on clozapine who have also received a benzod iaz-
epine (34 ,35). At this time, however, th ere is no ab solute con t ra ind icat ion to th e
conc urrent us e of benzodiaz ep ines with c1ozapine.
Adverse Efficts
Agra nulocy tos is is the primary concern with th e use of c1ozapine; a nd th e ex tent
to whi ch patients are monitored highlights th e con cern ove r this ge ne ra lly reversible
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but pot entially fatal adverse eve n t (21 ,36). Weekl y WB Cs are mandatory in a ll
patients on c1ozapine, which all ows for th e ea rly det ecti on ofle ukop enia or g ra nulocy-
top enia, should it occur. However, it sho uld be not ed th a t fluc tuat ions in whit e blood
coun ts a re com mo n in patients on c1ozapine, but a ny downwa rd trend in counts
should be closely scru t inized . The incid en ce of agranulocytosis is abou t 0.6 percent,
a nd leukopenia 1.8 percent (21) . The mech anism of ag ra nulocytosis is unk nown and
it do es not appe a r to be dos e-related. The vast maj ority of cases have occured within
th e first 6 months of th erap y, but th ere have been isolated report s of agranulocytosis
occuring in patients a fte r 15 months of treatment. Recovery gene ra lly occurs within
three weeks following discontinuation of cloza pine (22) .
Clozapine, like typi cal antipsychotic drugs , lowers th e se izu re t hreshold and ma y
pr ecipit at e se izu res . U nlike ag ra nulocytos is, this is clearly a dos e-related ph enom-
eno n, with th e incid en ce ran gin g from 0.6 percent in pa ti ents on less than 300 mg per
day, to 14 percent in patients taking ove r 600 mg per day (22). In addition to th e
abso lu te do se of c1ozapine, th e rate of titration is a lso a major factor affecting th e
incid en ce of seizures. 111 patients a t high risk or wh o a re on mor e th an 600 mg of
cloza pine a da y, prophlaxis with a n a nt iconvulsa n t, such as va lproic acid , should be
cons ide re d . If a se izu re does occur, th e me d ica t ion may be reinstitut ed at hal f th e
pr evious dose a fter a n an t iconvulsa n t is adde d .
There are numerou s other adverse effec ts du e to th e an tagonis tic properties of
clozapine a t histaminergic, noradren ergic and choline rg ic receptors. The incidence of
th ese effec ts varies a mo ng publish ed rep orts, but th ey include: seda t ion, ta chycardia ,
ort hos tat ic hypot en sion , cons t ipa t ion, di zzin ess, sia lorrhea (paradox ica l, cons ide ring
clozapine is a pot ent mu scarinic a n tagonist), hyperthermi a and weigh t gain, among
othe rs. While th ese side effec ts may be bothersome, th ey rarely necessita te stopping
th e medi cation, gen erally improve with con tinue d treatment , ca n sometimes be
managed with adj unc t ive medi cation s, a nd may be minimi zed wi th slow titration of
th e drug.
CONC LUSION
The treatm ent of schizo phre nia has been grea t ly enhanced by th e recent
ex plosion of resea rc h in neu roscien ce . The belief th at schizophrenia is purely an
illn ess of DA hyperact ivit y is no longer unive rsally accep ted. C learly som e sym pto ms
may be expla ine d by DA hyperacti vit y, but ot he rs appear to be secondary to
hypoactive DA circ uits . Thus, th e beli ef that D2 blockade is th e most import an t factor
in th e treatment of schizo phre nia is a lso losin g widespread support. Although D2
blockad e st ill seems to play a major ro le in th e t reat men t ofposit ive symptoms, t he re
is sufficien t data to support a role for D 1 receptor blockad e as well. T he conce pt of
negative sym pto ms and th e success of drugs th at are 5-HT 2 a ntagonists in th e
treatm ent of th ese sym ptoms is th e st ro nges t evide nce to dat e suppo rting a putative
neurotran smitt er abno rmality other th an DA in schizophrenia. Furth ermore, th e
conce p t of " ne uro t ra ns mitter ba la nce ," which emphas izes th e int eract ion between
different neu rotran sm itter systems, as being im portan t for normal br ain fun cti on
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and a lte re d in patients with schizophre nia is ga ining wid espread acceptance among
lead ing research ers in th e field . Thus, like clozapine, newer med icat ion s for the
treatm ent of schizophrenia will not be pure D2 a ntagonists. T o th e cont rary, newer
an t ipsychot ics will have less D2 blockade, more D 1 a nd 5-HT 2 blockad e, an d hopefully
less adren ergic, cho line rg ic, a nd histaminergic blockad e.
In review, num erous nondopaminergic syste ms have been im plica ted in th e
pa th ophysiology of schizophrenia, including those that uti lize th e neurotran smi tt ers
serotonin, rr-opio id. : neuroten sin, and N-methyl-D-asp artate. This has led to t he
development of a new ge ne ra t ion ofdrugs for th e treatment of this major psychia t ric
illn ess. Clozapine is th e first a typica l a ntipsyc ho t ic th at has proven to be effective in
schizophrenia, eve n in those patients who are otherwise treatment-r esist an t to
typi ca l a nt ipsychotic drugs. Furthermore, clozapine improves nega tive, as well as
positive, sym pto ms of schizo phre nia, a nd has little pot ential for inducing movement
disorders.
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